Table 1 Population characteristics
|  | NTD-Haplo (n = 186) | SUCBT (n = 147) | p value |
|---|---|---|---|
Follow-up, months median (range) | 22.07 (0–96.3) | 24.42 (0–83.1) |  |
HSCT year, median (range) | 2014 (2008–2015) | 2011 (2007–2015) | < 0.001 |
Age, years. median (range) | 44.3 (18.5–66.1) | 42.6 (18–67.9) | 0.046 |
Recipient sex | |||
 Male | 85 (45.7%) | 65 (44.2%) | 0.787 |
 Female | 101 (54.3%) | 82 (55.8%) |  |
 Missing | 0 | 6 |  |
Karnofsky performance status | |||
 < 90 | 21 (12.5%) | 15 (15.31%) | 0.519 |
 ≥ 90 | 147 (87.5%) | 83 (84.69%) |  |
 Missing | 18 | 49 |  |
Interval from diagnosis to HSCT, months, median (range) | 6.6 (2.1–189.6) | 6 (3–214.2) | 0.097 |
Disease status at HSCT | |||
 CR1 | 130 (69.9%) | 113 (76.9%) | 0.154 |
 CR2 | 56 (30.1%) | 34 (23.1%) |  |
MRC risk classification | |||
 Good | 16 (8.6%) | 13 (8.8%) | 0.762 |
 Intermediate | 67 (36.0%) | 60 (40.8%) |  |
 Poor | 19 (10.2%) | 16 (10.9%) |  |
 Missing | 84 (45.2%) | 58 (39.5%) |  |
Female donor to male recipient | |||
 No | 143 (76.9%) | 108 (76.6%) | 0.952 |
 Yes | 43 (23.1%) | 33 (23.4%) |  |
Recipient CMV serostatus |  |  | < 0.001 |
 Negative | 35 (19.1%) | 29 (25.9%) |  |
 Positive | 148 (80.9%) | 83 (74.1%) |  |
 Missing | 3 | 35 |  |
In-vivo T cell depletion (ATG) | |||
 No | 131 (71.2%) | 13 (9.0%) | < 0.001 |
 Yes | 53 (28.8%) | 131 (91.0%) |  |
 Missing | 2 | 3 |  |